Norethindrone Compounded vs Branded: What Women Need to Know

What Is Norethindrone Acetate and Why Does the Branded vs. Compounded Question Matter?

Norethindrone acetate is a synthetic 19-nortestosterone progestin that your body converts, in part, to ethinyl estradiol, making it biologically more potent per milligram than norethindrone base. The FDA-approved product, Aygestin 5 mg, has a well-documented pharmacokinetic profile: peak plasma concentration reaches roughly 26 ng/mL within 2 hours of a 5 mg oral dose, with a half-life of approximately 8 hours [1].

Compounded formulations of norethindrone acetate are mixed by a licensed compounding pharmacy without FDA pre-market review of potency, sterility, or bioavailability. That distinction matters clinically because even small deviations in progestin dose can mean inadequate endometrial suppression, breakthrough bleeding, or unexpected side effects.

The question of compounded vs. Branded is not abstract for women. It comes up when a prescriber or patient is looking for a lower dose, a non-standard route such as a topical cream or troche, or a product free of a specific inactive ingredient. Each of those reasons deserves honest scrutiny.

How Norethindrone Acetate Works: Sex-Specific Physiology

Progestogenic and androgenic effects in women

Norethindrone acetate binds progesterone receptors in the endometrium and suppresses estrogen-driven proliferation. It also carries moderate androgenic activity, which distinguishes it from progestogens such as dydrogesterone or micronized progesterone. That androgenicity can produce acne or mood changes in androgen-sensitive women, but it also makes norethindrone acetate effective at suppressing gonadotropins and reducing ovarian androgen output in conditions like polycystic ovary syndrome (PCOS).

The estrogen-conversion factor

Norethindrone acetate is partially converted to ethinyl estradiol in the gut wall and liver. A 5 mg oral dose yields measurable circulating ethinyl estradiol. This conversion does not occur with topical or vaginal compounded preparations to the same degree, which is one argument some clinicians make for alternative delivery routes. The clinical significance of that conversion at standard therapeutic doses remains incompletely studied in women specifically, and you should discuss it with your provider if you have a history of estrogen-sensitive conditions.

Menstrual cycle effects

In women with intact ovarian function, norethindrone acetate taken continuously suppresses the luteinizing hormone (LH) surge and can inhibit ovulation at doses above 0.35 mg daily. The 5 mg dose used for endometriosis or heavy menstrual bleeding (HMB) reliably produces a progestin-dominant, hypoestrogenic environment that leads to decidualization and eventual atrophy of ectopic or eutopic endometrium.

The Branded Product: Aygestin 5 mg

Aygestin is the only FDA-approved norethindrone acetate product in the United States indicated for endometriosis, secondary amenorrhea, and abnormal uterine bleeding due to hormonal imbalance. The labeling specifies [2]:

• Endometriosis: 5 mg daily for 2 weeks, increased by 2.5 mg every 2 weeks up to 15 mg daily, continued for 6 to 9 months
• Abnormal uterine bleeding and secondary amenorrhea: 2.5 to 10 mg daily for 5 to 10 days during the second half of the theoretical menstrual cycle

For heavy menstrual bleeding specifically, the Cochrane review by Lethaby et al. (2013) evaluated progestins across multiple regimens and found that luteal-phase progestins produced a mean reduction in menstrual blood loss of approximately 87%, while long-cycle (days 5 to 26) norethindrone regimens showed even greater reductions, with women preferring the long-cycle approach over shorter luteal-phase schedules [3].

What FDA approval actually guarantees

When you fill a prescription for Aygestin at a standard pharmacy, you receive a product that:

1. Has passed FDA manufacturing quality standards under current Good Manufacturing Practice (cGMP)
2. Has a defined potency range (90 to 110% of labeled dose per FDA dissolution specifications)
3. Has labeling reviewed for accuracy of safety information, including the black-box pregnancy warning
4. Can be traced through a regulated supply chain if a recall is needed

None of those assurances apply to compounded norethindrone acetate by default.

Compounded Norethindrone Acetate: What It Is and Where It Falls Short

Compounded norethindrone acetate is prepared by a 503A or 503B compounding pharmacy. A 503A pharmacy compounds for an individual patient under a specific prescription. A 503B outsourcing facility may produce larger batches but still does not undergo the same pre-market FDA scrutiny as a drug manufacturer.

Why potency variability matters for you

A 2022 analysis of compounded hormone preparations by the FDA found that 34% of tested samples fell outside acceptable potency ranges, with some containing as little as 67% or as much as 133% of the labeled dose [4]. For a progestin like norethindrone acetate, where endometrial protection depends on reaching a minimum threshold concentration, a sub-potent product could mean inadequate suppression, uncontrolled bleeding, or, in the context of menopausal hormone therapy, unprotected endometrial stimulation from concurrent estrogen.

Common reasons women are prescribed compounded norethindrone acetate

• A prescriber wants a dose lower than the available 5 mg tablet (for example, 1 mg or 2 mg daily for HRT add-back therapy in women on GnRH agonists)
• A patient has a documented allergy to an inactive ingredient in Aygestin (lactose, starch, or FD&C dye)
• A prescriber wants a topical or vaginal delivery route, believing it avoids first-pass conversion to ethinyl estradiol
• Cost: compounded versions can appear cheaper without insurance, though price differences vary by pharmacy

What the evidence does NOT support

There is no published randomized controlled trial demonstrating that compounded norethindrone acetate at any dose or route achieves equivalent endometrial suppression, cycle control, or pain reduction compared to Aygestin in women with endometriosis or HMB. That absence of comparative data is not a minor gap. ACOG Practice Bulletin 114 on endometriosis names norethindrone acetate as a recommended treatment but refers to the studied oral form, not compounded alternatives [5].

The WomanRx editorial team developed the following decision framework after reviewing FDA compounding guidance, the Cochrane HMB progestin data, and ACOG endometriosis and HMB practice bulletins. No single published source presents this integrated comparison in this format.

Compounded vs. Branded Norethindrone Acetate: A Clinical Decision Framework for Women

| Clinical scenario | Recommended choice | Rationale | |---|---|---| | Endometriosis, confirmed by laparoscopy | Branded Aygestin 5 mg | Direct trial evidence; predictable PK | | Heavy menstrual bleeding, no contraindication | Branded Aygestin 5 mg | Cochrane-supported efficacy | | Add-back therapy with GnRH agonist (needs <5 mg dose) | Compounded may be reasonable | No FDA-approved low-dose oral product exists | | Documented excipient allergy to Aygestin components | Compounded with pharmacist verification | Narrow medical necessity | | Menopausal HRT progestogen component | Branded preferred; compounded only if no alternative | Endometrial protection requires verified potency | | Cost alone as reason | Branded preferred; explore manufacturer coupons | Potency risk outweighs cost savings |

Life Stage Guide: How Indication and Dosing Differ Across Your Reproductive Years

Reproductive years (ages 18 to approximately 44)

In women with regular cycles, norethindrone acetate is most commonly prescribed for endometriosis-related pelvic pain, heavy menstrual bleeding, or secondary amenorrhea. ACOG recommends oral progestins including norethindrone as a first-line medical option for HMB in women who do not want or cannot tolerate an intrauterine device [6]. At 5 mg daily from days 5 to 26 of the cycle, norethindrone acetate reduced mean blood loss by 83% in one clinical comparison cited in the Cochrane review [3].

For PCOS, norethindrone is not a first-line ovulation inducer, but it is used to induce withdrawal bleeds and protect the endometrium in women with chronic anovulation, where unopposed estrogen increases the risk of endometrial hyperplasia. The androgenic profile of norethindrone acetate means it may worsen acne or hirsutism in androgen-sensitive women with PCOS; micronized progesterone or a less androgenic progestin may be preferable in that subset.

Trying to conceive

Norethindrone acetate is not used during active conception attempts. If you are trying to get pregnant, norethindrone should be stopped and an appropriate waiting period discussed with your provider before attempting conception. The drug is cleared from plasma within 24 to 48 hours of discontinuation, but the labeling does not specify a minimum washout period before attempting pregnancy.

Perimenopause (approximate age range 45 to 52)

During perimenopause, norethindrone acetate serves a dual role: managing erratic or heavy menstrual bleeding driven by anovulatory cycles, and providing the progestogen component of menopausal hormone therapy if systemic estrogen is added. Unopposed estrogen in a woman with a uterus carries a well-documented risk of endometrial hyperplasia and cancer; adding a progestogen like norethindrone acetate counteracts that risk [7].

The dose needed for endometrial protection in the context of HRT (typically 0.35 to 1 mg daily, or 5 mg for 10 to 14 days per cycle in a sequential regimen) is lower than the 5 mg continuous dose used for endometriosis. No FDA-approved tablet delivers less than 5 mg of norethindrone acetate as a standalone product, which is the primary clinical justification for compounding in this life stage.

Post-menopause

In post-menopausal women using systemic estrogen, norethindrone acetate at 0.1 mg daily (as part of the combination tablet Activella, which contains estradiol 1 mg plus norethindrone acetate 0.5 mg, or Lopreeza, estradiol 1 mg plus norethindrone acetate 0.5 mg) is FDA-approved and avoids the need for compounding entirely. If a prescriber is recommending a compounded low-dose norethindrone acetate cream or troche for post-menopausal endometrial protection, ask explicitly whether a combination FDA-approved tablet would meet the same clinical goal.

Pregnancy and Lactation: A Required Warning

Norethindrone acetate is FDA Pregnancy Category X. It is contraindicated during pregnancy.

This is not a theoretical risk. Norethindrone and other 19-nortestosterone derivatives have been associated with virilization of female fetuses when administered in early pregnancy, including clitoral enlargement and labial fusion [8]. The risk window is primarily the first trimester, during genital organogenesis.

If you are of reproductive age and taking norethindrone acetate

You must use reliable contraception throughout the course of treatment. Norethindrone acetate at 5 mg daily inhibits ovulation but is not approved as a standalone contraceptive at that dose, and the inhibition is not consistent enough across all women to substitute for a defined contraceptive method. ACOG guidance on contraception recommends not relying on therapeutic progestins prescribed for other indications as contraception unless the product is specifically labeled for that use [9].

Lactation

Norethindrone acetate is detectable in breast milk. Norethindrone (the related progestin-only pill) is the preferred progestin-only contraceptive in breastfeeding women because the amount transferred to the infant is considered low and no adverse effects on infant growth or development have been consistently demonstrated at standard contraceptive doses [10]. However, the 5 mg therapeutic dose of norethindrone acetate used for HMB or endometriosis delivers substantially more drug than the 0.35 mg progestin-only pill dose. Data on infant exposure at these higher doses is limited. Discuss the risk-benefit with your provider and a lactation specialist before continuing 5 mg norethindrone acetate while breastfeeding.

Contraception requirement summary

• If taking norethindrone acetate 5 mg for endometriosis or HMB: use a reliable non-hormonal or hormonal contraceptive method in parallel
• The drug itself should not be counted as your contraceptive
• If pregnancy is suspected during treatment: stop the drug and contact your provider immediately

Who This Is Right For, and Who Should Use Caution

Women who are likely good candidates for branded norethindrone acetate

• Diagnosed endometriosis (laparoscopically confirmed or clinically suspected with classic symptoms) in the reproductive years
• Heavy menstrual bleeding confirmed by validated assessment (PBAC score above 100 or measured blood loss above 80 mL per cycle) who have tried or declined an IUD
• Perimenopausal women with anovulatory HMB not requiring contraception
• Women needing progestogen opposition in HRT who cannot tolerate oral micronized progesterone (Prometrium) due to sedation or allergy

Women for whom norethindrone acetate may not be appropriate

• Active or history of thromboembolic disease: norethindrone acetate carries a class warning for VTE risk that is greater with oral progestins than with micronized progesterone in observational data [11]
• Androgen-sensitive conditions where worsening is a concern: norethindrone acetate has androgenic activity that may worsen acne, seborrhea, or hirsutism
• Women who are pregnant or planning pregnancy in the near term
• Women with liver disease: norethindrone acetate undergoes extensive hepatic metabolism and is contraindicated with active liver impairment [2]
• Women with a history of hormone-sensitive breast cancer: discuss with your oncologist before any progestin

Conditions where compounded norethindrone acetate may have a narrow role

• Add-back therapy with leuprolide or other GnRH agonists, where the target dose is 1 to 5 mg daily and the treating team accepts the potency uncertainty
• Documented excipient allergy verified by an allergist, with no tolerable alternative progestin available

What Regulators and Guidelines Actually Say

The FDA's position on compounded hormones is explicit. The agency's 2020 statement on compounded hormone therapy states that compounded preparations "are not FDA-approved" and that "FDA has not evaluated them for safety, effectiveness, or quality" [12]. The FDA also notes that compounded hormones should not be promoted as safer or more effective than FDA-approved products without evidence.

The Menopause Society (formerly NAMS) 2022 position statement on hormone therapy states: "The Menopause Society does not recommend compounded hormone therapy for the routine management of menopause due to concerns about safety and lack of efficacy data," while acknowledging a narrow role for women with documented specific medical need [13].

"Clinicians should inform patients that compounded hormones are not regulated by the FDA and that there are no data from clinical trials establishing safety and efficacy for these products," according to the Menopause Society 2022 statement [13].

From an ACOG perspective, the organization's clinical guidance on endometriosis and on HMB both cite evidence for oral norethindrone acetate specifically, with no endorsement of compounded alternatives as equivalent substitutes [5] [6].

Practical Guidance: Questions to Ask Your Prescriber

Before accepting a prescription for compounded norethindrone acetate, these questions help you make an informed decision:

1. Is there a specific medical reason an FDA-approved product cannot meet my needs?
2. If the reason is dose, does an approved combination product (such as Activella) achieve the same clinical goal?
3. What pharmacy will compound this, and is it PCAB-accredited?
4. Will the pharmacy provide a certificate of analysis confirming potency?
5. How will we monitor whether this is working (endometrial biopsy, cycle tracking, symptom diary)?

If your prescriber cannot answer question 1 with a specific reason tied to your individual clinical situation, branded Aygestin is almost certainly the better choice.

Cost, Access, and Insurance Realities

Aygestin 5 mg tablets are available as a generic (norethindrone acetate 5 mg) from multiple manufacturers, which has reduced cost substantially. The generic typically runs $30 to $80 for a 30-day supply without insurance. Most insurance plans cover generic norethindrone acetate when the diagnosis code supports the indication.

Compounded norethindrone acetate may appear cheaper at first glance, particularly for low-dose formulations not covered by insurance, but the absence of potency verification and the potential need for repeat monitoring (endometrial biopsy, ultrasound) if bleeding is uncontrolled can offset those savings quickly.

Generic norethindrone acetate 5 mg should be your starting point for cost conversations with your provider. Manufacturer patient assistance programs exist for the branded version if generic is not accessible in your area.